Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study

被引：0
|
作者：
Su, J-Y. [1 ]
Liu, S. [2 ]
Xu, X-L. [3 ]
Ou, J-J. [4 ]
Li, L. [1 ]
Ma, Y-L. [5 ]
Ma, L. [1 ]
Zhong, J-H. [1 ]
机构：
[1] Guangxi Med Univ, Canc Hosp, Hepatobiliary Surg, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 8, Hepatobiliary Surg, Guigang, Peoples R China
[3] Peoples Hosp Wuzhou, Med Records & Stat Room, Wuzhou, Peoples R China
[4] Wuzhou Peoples Hosp, Hepatobiliary Surg, Wuzhou, Peoples R China
[5] Guangxi Med Univ, Canc Hosp, Pathol, Nanning, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213P
引用
收藏
页码：S1485 / S1486
页数：2
相关论文
共 50 条
  • [1] Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study
    Su, J-Y.
    Liu, S.
    Xu, X-L.
    Li, L.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
  • [2] Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
    Su, Jia-Yong
    Liu, Shao-Ping
    Xu, Xiao-Ling
    Ou, Jun-Jie
    Ye, Po-Hua
    Zhao, Bin-Tong
    Chen, Jia-Song
    Luo, Qiu-Mei
    Liu, Jin-Rong
    Tang, Fei-Min
    Li, Jian-Rong
    Yang, Da-Long
    Deng, Zhu-Jian
    Pan, Li-Xin
    Li, Yao-Jie
    Li, Le
    Qin, Zhen-Ming
    Liang, Xiu-Mei
    Ma, Yi-Li
    Ma, Liang
    Zhong, Jian-Hong
    LIVER CANCER, 2024,
  • [3] ADJUVANT IMMUNE CHECKPOINT INHIBITORS FOR HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGH-RISK OF POSTOPERATIVE RECURRENCE: A PROSPECTIVE COHORT STUDY (PREVENT)
    Li, Le
    Huang, Shan
    Qi, Lu-Nan
    Xiang, Bang-De
    Ma, Liang
    Zhong, Jian-Hong
    HEPATOLOGY, 2023, 77 (05) : E132 - E133
  • [4] Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
    Le Li
    Pei-Sheng Wu
    Xiu-Mei Liang
    Kang Chen
    Guan-Lan Zhang
    Qi-Bin Su
    Rong-Rui Huo
    Rong-Wei Xie
    Shan Huang
    Liang Ma
    Jian-Hong Zhong
    Journal of Gastroenterology, 2023, 58 : 1043 - 1054
  • [5] Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
    Li, Le
    Wu, Pei-Sheng
    Liang, Xiu-Mei
    Chen, Kang
    Zhang, Guan-Lan
    Su, Qi-Bin
    Huo, Rong-Rui
    Xie, Rong-Wei
    Huang, Shan
    Ma, Liang
    Zhong, Jian-Hong
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (10) : 1043 - 1054
  • [6] Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study
    Li, Le
    Liang, Xiu-Mei
    Chen, Kang
    Zhang, Guan-Lan
    Huang, Shan
    Ma, Liang
    Zhong, Jian-Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Treatment duration of adjuvant immune checkpoint inhibitor in hepatocellular carcinoma after curative resection: A prospective cohort study
    Pan, Li-Xin
    Su, Jia-Yong
    Li, Le
    Fan, Xiao-Hui
    Ma, Liang
    Zhong, Jian-Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study
    Zhou, Liuyu
    Zhang, Yuhong
    Zheng, Jie
    Ruan, Minghao
    Zhang, Jin
    Li, Yao
    Jin, Riming
    Wu, Dong
    Sun, Hanyong
    Zhang, Jianjun
    Wang, Ruoyu
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [9] Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): Preliminary analysis of a prospective cohort study
    Liu, J.
    Zeng, D.
    Cheng, Y.
    Li, Y.
    Zhang, M.
    Song, S.
    Huang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1490 - S1490
  • [10] Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study
    Guo, Zhiyong
    Liu, Yao
    Ling, Qi
    Xu, Leibo
    Wang, Tielong
    Zhu, Jiaxing
    Lin, Yimou
    Lu, Xinjun
    Qu, Wei
    Zhang, Fan
    Zhu, Zhijun
    Zhang, Jian
    Jia, Zehua
    Zeng, Ping
    Wang, Wenjing
    Sun, Qiang
    Luo, Qijie
    Hu, Zemin
    Zheng, Zhouying
    Jia, Yingbin
    Li, Jian
    Zheng, Yujian
    Wang, Mengchao
    Wang, Shaoping
    Han, Zemin
    Yu, Sheng
    Li, Chuanjiang
    Zhang, Shuhua
    Xiong, Jun
    Deng, Feiwen
    Liu, Ying
    Chen, Huanwei
    Wang, Yanfeng
    Li, Ling
    Liang, Wenjin
    Schlegel, Andrea
    Nashan, Bjorn
    Liu, Chao
    Zheng, Shusen
    He, Xiaoshun
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (10) : 1837 - 1856
12345